- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Eighth Edition Explores Impact of COVID-19 on Oncologists
Survey shows providers have embraced telemedicine, but are experiencing higher rates of burnout.
In response to the COVID-19 pandemic, U.S. oncologists have adjusted patient care by embracing telemedicine and switching more patients to oral therapies to limit office visits—but personally, more oncologists may be experiencing burnout due to the loss of face-to-face interactions with patients, according to new research from Cardinal Health Specialty Solutions.
These findings were released today in the eighth edition of Oncology Insights, a research-based report series analyzing the views of more than 190 U.S. oncologists via surveys conducted in September through November 2020. This issue explores how oncologists are adapting their practices and caring for patients during the pandemic – and points to changes that may continue after COVID-19.
Nearly all participating oncologists (97%) said they used telemedicine during a peak stage of the pandemic, and they are generally satisfied with the experience. Nearly six in 10 participating oncologists said their telemedicine experience has been “highly positive” (10%) or “better than expected” (49%). About 80% of participating oncologists said they expect to continue using telemedicine with some patients after the pandemic.
For more information, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
